OnabotulinumtoxinA for Pediatric Migraine

Ali, 2019, Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients, Cureus, 11, e343 Allergan. (2021). BOTOX (onabotulinumtoxinA): Pescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5318lbl.pdf. Andraka-Christou, 2018, A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices, International Journal of Drug Policy, 54, 9, 10.1016/j.drugpo.2017.11.021 Atraszkiewicz, 2022, The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time, British Journal of Pain, 16, 41, 10.1177/20494637211014544 Aurora, 2010, OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial, Cephalalgia, 30, 793, 10.1177/0333102410364676 Barad, 2019, Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain, Regional Anesthesia & Pain Medicine, 44, 660, 10.1136/rapm-2018-100196 Burch, 2021, The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys, Headache: The Journal of Head and Face Pain, 61, 60, 10.1111/head.14024 Burstein, 2020, Mechanism of action of onabotulinumtoxinA in chronic migraine: A narrative review, Headache: The Journal of Head and Face Pain, 60, 1259, 10.1111/head.13849 Chan, 2009, Botox treatment for migraine and chronic daily headache in adolescents, Journal of Neuroscience Nursing, 41, 235, 10.1097/JNN.0b013e3181aaa98f Chen, 2012, Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments, Toxins, 4, 913, 10.3390/toxins4100913 Colloca, 2019, The placebo effect in pain therapies, Annual Review of Pharmacology and Toxicology, 59, 191, 10.1146/annurev-pharmtox-010818-021542 Dallavalle, 2020, Migraine symptoms improvement during the COVID-19 lockdown in a cohort of children and adolescents, Frontiers in Neurology, 11, 10.3389/fneur.2020.579047 Diener, 2010, OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial, Cephalalgia, 30, 804, 10.1177/0333102410364677 Dodick, 2007, Migraine prevention, Practical Neurology, 7, 383, 10.1136/jnnp.2007.134023 Goenka, 2022, Is Botox right for me: When to assess the efficacy of the Botox injection for chronic migraine in pediatric population, Neuropediatrics, 53, 344, 10.1055/a-1832-9168 Hickman, 2015, Prevention for pediatric and adolescent migraine, Headache: The Journal of Head and Face Pain, 55, 1371, 10.1111/head.12699 Horton, 2021, Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: A mixed-methods study of patients and caregivers, Arthritis Care & Research, 73, 374, 10.1002/acr.24129 Iannone, 2022, Emerging pharmacological treatments for migraine in the pediatric population, Life, 12, 536, 10.3390/life12040536 Javanbakht, 2020, Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system, PLos One, 15, 10.1371/journal.pone.0241615 Kabbouche, 2012, OnabotulinumtoxinA in pediatric chronic daily headache, Current Neurology and Neuroscience Reports, 12, 114, 10.1007/s11910-012-0251-1 Karian, 2020, External devices for headache, 99 Karian, 2020, Preventive medications, 72 Kiarashi, 2021, Factors associated with, and mitigation strategies for, health care disparities faced by patients with headache disorders, Neurology, 97, 280, 10.1212/WNL.0000000000012261 Lampl, 2018, OnabotulinumtoxinA in the treatment of refractory chronic cluster headache, Journal of Headache and Pain, 19, 45, 10.1186/s10194-018-0874-y Lateef, 2019, Physical–mental comorbidity of pediatric migraine in the Philadelphia neurodevelopmental cohort, Journal of Pediatrics, 205, 210, 10.1016/j.jpeds.2018.09.033 Law, 2019, Economic impact of headache and psychiatric comorbidities on healthcare expenditures among children in the United States: A retrospective cross-sectional study, Headache: The Journal of Head and Face Pain, 59, 1504, 10.1111/head.13639 Ning, 2019, The insurance approval process for proton radiation therapy: A significant barrier to patient care, International Journal of Radiation Oncology, Biology, Physics, 104, 724, 10.1016/j.ijrobp.2018.12.019 Oskoui, 2019, Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society, Neurology, 93, 500, 10.1212/WNL.0000000000008105 Overeem, 2021, Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: A systematic review with meta-analysis, CNS Drugs, 35, 805, 10.1007/s40263-021-00834-9 Papetti, 2019, Prophylactic treatment of pediatric migraine: Is there anything new in the last decade?, Frontiers in Neurology, 10, 771, 10.3389/fneur.2019.00771 Perfitt, 2020, Placebo effect in the management of chronic pain, BJA Education, 20, 382, 10.1016/j.bjae.2020.07.002 Powers, 2017, Trial of amitriptyline, topiramate, and placebo for pediatric migraine, New England Journal of Medicine, 376, 115, 10.1056/NEJMoa1610384 Reuter, 2019, Non-invasive neuromodulation for migraine and cluster headache: A systematic review of clinical trials, Journal of Neurology, Neurosurgery & Psychiatry, 90, 796, 10.1136/jnnp-2018-320113 Santana, 2021, Experience of botulinum toxin A injections for chronic migraine headaches in a pediatric chronic pain clinic, Journal of Pediatric Pharmacology and Therapeutics, 26, 151, 10.5863/1551-6776-26.2.151 Schantz, 1997, Botulinum toxin: The story of its development for the treatment of human disease, Perspectives in Biology and Medicine, 40, 317, 10.1353/pbm.1997.0032 Schroeder, 2012, Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain, Neuropediatrics, 43, 339, 10.1055/s-0032-1329612 Shah, 2018, Onabotulinumtoxin A (BOTOX®) for prophylaCTIC treatment of pediatric migraine: A retrospective longitudinal analysis, Journal of Child Neurology, 33, 580, 10.1177/0883073818776142 Shapiro, 1998, Botulism in the United States: A clinical and epidemiologic review, Annals of Internal Medicine, 129, 221, 10.7326/0003-4819-129-3-199808010-00011 Silberstein, 2002, Clinical results of botulinum toxin type a treatment of migraine headache, Aesthetic Surgery Journal, 22, 91, 10.1067/maj.2002.121958 Simmons, 2014, Pain and placebo in pediatrics: A comprehensive review of laboratory and clinical findings, Pain, 155, 2229, 10.1016/j.pain.2014.08.036 Stein, 2019, Worries about discontinuing buprenorphine treatment: Scale development and clinical correlates, The American Journal on Addictions, 28, 270, 10.1111/ajad.12884 Stovner, 2008, Impact of headache in Europe: A review for the Eurolight project, The Journal of Headache and Pain, 9, 139, 10.1007/s10194-008-0038-6 Szperka, 2018, Recommendations on the use of Anti-CGRP monoclonal antibodies in children and adolescents, Headache, 58, 1658, 10.1111/head.13414 Talbet, 2022, OnabotulinumtoxinA for the treatment of headache: An updated review, Journal of Integrative Neuroscience, 21, 037, 10.31083/j.jin2101037 Tepper, 2017, Migraine in children, Headache: The Journal of Head and Face Pain, 57, 1021, 10.1111/head.13091 Ting, 2004, The story of Clostridium botulinum: From food poisoning to Botox, Clinical Medicine, 4, 258, 10.7861/clinmedicine.4-3-258 Torrens, 1998, Clostridium botulinum was named because of association with “sausage poisoning, BMJ, 316, 10.1136/bmj.316.7125.151c Tsze, 2022, Clinical interpretation of self-reported pain scores in children with acute pain, The Journal of Pediatrics, 240, 192, 10.1016/j.jpeds.2021.08.071 Turner, 2021, Association of headache with school functioning among children and adolescents in the United States, JAMA Pediatrics, 175, 522, 10.1001/jamapediatrics.2020.5680 Vandervorst, 2021, CGRP monoclonal antibodies in migraine: An efficacy and tolerability comparison with standard prophylactic drugs, Journal of Headache and Pain, 22, 128, 10.1186/s10194-021-01335-2 Vikelis, 2018, Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment, Journal of Headache and Pain, 19, 87, 10.1186/s10194-018-0918-3 Williams, 2019, Management of chronic migraine and occipital neuralgia in post 9/11 combat veterans, Military Medicine, 184, e207, 10.1093/milmed/usy405 Wöber-Bingöl, 2014, The global burden of headache in children and adolescents – developing a questionnaire and methodology for a global study, Journal of Headache and Pain, 15, 86, 10.1186/1129-2377-15-86 Wu, 2020, The efficacy and safety of topiramate in the prevention of pediatric migraine: An updated meta-analysis, Frontiers in Pediatrics, 8, 28, 10.3389/fped.2020.00028 Yerry, 2015, Onabotulinum toxin A for the treatment of headache in service members with a history of mild traumatic brain injury: A cohort study, Headache, 55, 395, 10.1111/head.12495 Zizzo, 2021, Fear of stopping” vs “wanting to get off the medication”: Exploring women's experiences of using domperidone as a galactagogue - a qualitative study, International Breastfeeding Journal, 16, 92, 10.1186/s13006-021-00438-5